Mid-Day Breakouts Report - Wednesday, June 29th, 2022

<<<Previous Mid Day Report	Next Mid Day Report >>>
<<<Previous After Market Report	Next After Market Report >>>

You are not logged in.
This means you CAN ONLY VIEW reports that were published prior to Friday, February 23, 2024.
You MUST UPGRADE YOUR MEMBERSHIP if you want to see any current reports.

MIDDAY BREAKOUTS REPORT - WEDNESDAY, JUNE 29TH, 2022
Previous Mid Day Report Next Mid Day Report >>>

DOW 30966.62 19.63 (0.06%) | NASDAQ 11156.12 -25.42 (-0.23%) | S&P 500 3815.21 -6.34 (-0.17%)

Time of Screening : 6/29/2022 12:23:53 PM Report Released : 6/29/2022 12:32:34 PM
Price is: Above 52W High and Less Than 52W High but within 15% of the 52 Week High
Volume Is: At least 50% of 50 Day Average at the time of the screening.
More details about this report...

To View Current Notes and Data on currently Featured Stocks go to the latest
Featured Stocks Page

NONE OF OUR FEATURED STOCKS MET TODAY'S SCREENING CRITERIA FOR VOLUME AND PRICE ACTION.

Symbol - Exchange - Industry Group Company Name	Last	Chg	Day High	52 WK Hi	% From Hi	Volume % DAV	DAV
CCMP - NASDAQ - CHEMICALS - Specialty Chemicals Cabot Microelectronics	$174.44	-5.14 -2.86%	$176.35	$197.00	-11.45%	468,133 128.26%	365,000
Most Recent Note for CCMP - 6/29/2022 12:24:38 PM Consolidating in a tight range since M&A news 12/15/21. Reported earnings +13% on +12% sales revenues Mar '22 quarter versus the year ago period, and prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria). Annual earnings history (A criteria) included a downturn in FY '21.
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
HAE - NYSE - HEALTH SERVICES - Medical Instruments & Supplies Haemonetics Corp	$65.64	+1.65 2.58%	$65.86	$75.34	-12.87%	381,472 78.01%	489,000
Most Recent Note for HAE - 6/29/2022 12:26:23 PM Reported earnings +41% on +18% sales revenues for the Mar '22 quarter versus the year ago period. Fundamental concerns remain. Prior quarterly and annual earnings (C and A criteria) and sales revenue growth history is below guidelines of the fact-based investment system.
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
LRN - NYSE - Consumer Svcs-Education Stride Inc	$42.19	+4.42 11.70%	$42.35	$41.84	0.84%	1,876,713 283.06%	663,000
Most Recent Note for LRN - 6/29/2022 12:28:07 PM Gapped up and hit a new 52-week high with today's big volume-driven gain. Found support near its 200 DMA line while consolidating since last noted with caution in the 6/08/22 mid-day report - "Reported earnings +79% on +8% sales revenues for the Mar '22 quarter versus the year ago period. Faces some old resistance due to overhead supply up to the $52 level. Prior quarterly comparisons were not strong and steady above the +25% minimum earnings guideline (C criteria) and its annual earnings (A criteria) history has been up and down, not a match with the fact-based system's fundamental guidelines."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
NVO - NYSE - DRUGS - Drug Manufacturers - Other Novo Nordisk A/S Adr	$110.54	+2.24 2.07%	$111.21	$122.16	-9.51%	753,108 50.75%	1,484,000
Most Recent Note for NVO - 6/29/2022 12:28:32 PM This Denmark-based Medical - Ethical Drug firm is consolidating near its 50 and finding support near its 200 DMA line. Prior mid-day reports repeatedly cautioned members - "Fundamental concerns remain after it reported Mar '22 quarterly earnings +8% on +17% sales revenues versus the year ago period."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
OBCI - NASDAQ - CONSUMER NON-DURABLES - Cleaning Products Ocean Bio Chem Inc	$12.87	+0.01 0.08%	$12.87	$13.40	-3.96%	17,206 52.14%	33,000
Most Recent Note for OBCI - 6/29/2022 12:28:41 PM Gapped up on 6/22/22 following M&A news. Fundamental concerns remain. Noted with caution in prior mid-day reports - "Sales revenues growth and earnings history is not a match with the fact-based investment system's fundamental guidelines."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
RGP - NASDAQ - Comml Svcs-Consulting Resources Connection Inc	$19.70	-0.47 -2.33%	$20.17	$21.40	-7.94%	190,068 84.85%	224,000
Most Recent Note for RGP - 6/29/2022 12:30:32 PM There was a "negative reversal" on the prior session after it hit another new 52-week high. Feb '22 quarterly earnings rose +364% on +31% sales revenues versus the year ago period, its 3rd strong quarter.
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
SAFM - NASDAQ - FOOD & BEVERAGE - Meat Products Sanderson Farms Inc	$219.79	-0.12 -0.05%	$220.32	$221.63	-0.83%	159,535 52.14%	306,000
Most Recent Note for SAFM - 6/29/2022 12:30:45 PM Perched at its all-time high after heavy volume behind gains in recent weeks. Prior mid-day reports noted - "Reported very strong sales revenues and earnings increases in quarterly comparisons through Apr '22 versus the year ago periods. Sub par annual earnings (A criteria) history is not a match with the fact-based investment system's guidelines. Consolidating since M&A news 8/09/21 with Cargill."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
SHEL - NYSE - Oil&Gas-Integrated Shell Plc Ads	$52.94	-0.21 -0.40%	$54.30	$61.68	-14.17%	3,051,310 57.02%	5,351,000
Most Recent Note for SHEL - 6/29/2022 12:31:24 PM Violated its 50 DMA line and found support at its 200 DMA line ($50.38) after damaging volume-driven losses. Past 3 quarterly comparisons through Mar '22 were well above the +25% minimum earnings guideline (C criteria). Annual earnings history has been up and down.
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
USAK - NASDAQ - TRANSPORTATION - Trucking U S A Truck Inc	$31.06	+0.05 0.15%	$31.11	$31.67	-1.94%	502,495 228.41%	220,000
Most Recent Note for USAK - 6/29/2022 12:31:39 PM Gapped up on 6/24/22 M&A news. Recent quarterly comparisons through Mar '22 were strong but its prior earnings history is not a match with the fundamental guidelines of the fact-based investment system.
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M
VIVO - NASDAQ - DRUGS - Diagnostic Substances Meridian Bioscience Inc	$31.74	+0.32 1.02%	$31.23	$31.93	-0.60%	204,254 52.51%	389,000
Most Recent Note for VIVO - 6/29/2022 12:32:28 PM Volume-driven gains helped it hit a new 52-week high on 6/27/22. Prior mid-day reports cautioned members - "Quarterly earnings increases through Mar '22 versus the year ago periods have been below the +25% minimum guideline (C criteria). Up and down annual earnings (A criteria) history is not a match with the fact-based investment system's fundamental guidelines. On 4/18/08 it was dropped from the Featured Stocks list."
View all notes \| Alert me of new notes \| Company Profile \| SEC \| News \| Chart \| C A N S L I M

THESE ARE NOT BUY RECOMMENDATIONS! Comments contained in the body of this report are technical opinions only. The material herein has been obtained from sources believed to be reliable and accurate, however, its accuracy and completeness cannot be guaranteed. We are not an investment advisor, hence it does not endorse or recommend any securities or other investments. Any recommendation contained in this report may not be suitable for all investors and it is not to be deemed an offer or solicitation on our part with respect to the purchase or sale of any securities. All trademarks, service marks and trade names appearing in this report are the property of their respective owners, and are likewise used for identification purposes only.

This report is a service available only to active Paid Premium Members. You may opt-out of receiving report notifications at any time. Questions or comments may be submitted by writing to FactBasedInvesting.com c/o Premium Member Services 665 S.E. 10 Street, Suite 201 Deerfield Beach, FL 33441-5634 or by calling 954-785-1121.

We appreciate any feedback members may wish to send via the inquiry form here.